PLoS Pathog: CoVID19 patient antibody response helps vaccine design.

SEPTEMBER 12, 2020 /--- According to a study published September 10 in the journal PLOS Pathogens by Professor Wu Chao of Nanjing University School of Medicine, a comprehensive analysis of antibody responses in COVID-19 patients could provide information for the development of effective vaccines.
results showed a sharp decline in the mesoactive activity of antibodies in recovered patients within one month of discharge.
is facing unprecedented challenges for communities and economies affected by the growing COVID-19 pandemic.
currently, no vaccines or effective drugs have been approved to treat or prevent the disease.
understanding of antibody responses to SARS-CoV-2 will provide the basis for the development of effective treatments and preventive vaccines.
in the new study, researchers continuously monitored SARS-CoV-2 specific antibody responses in 19 non-severe and 7 severe COVID-19 patients for seven weeks, starting with the onset of the disease.
(Photo: www.pixabay.com) Most patients develop antibody reactions to SARS-CoV-2, with specific targets including viral nucleoproteins and tingling proteins.
Although 80.7% of patients with rehab COVID-19 had different levels of activity in antibodies to SARS-CoV-2, only a small percentage of patients produced antibodies with a medium activity.
results highlight the importance of carefully selecting blood samples from recovered patients using antibody-based and trials.
three to four weeks after discharge, the mesoactive activity of antibodies in recovered patients decreased significantly, indicating that recovered COVID-19 patients may be susceptible to SARS-CoV-2.
addition, severe COVID-19 patients have a large number of non-neutral antibodies, which may contribute to the enhanced response (ADE) of antibody-dependent infections.
the study provides important insights into serological testing, antibody-based interventions and vaccine design, the authors said.
(bioon.com) Source: Antibody responses in COVID-19 patients can guide vaccine design Original source: Chen Y, Tong X, Li Y, Gu B, Yan J, Liu Y, et al. (2020) A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog 16 (9): e1008796. doi.org/10.1371/journal.ppat.1008796.